The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.

A comprehensive 249-page veterinary diagnostics market report covering 15 countries and 32 companies has been released, forecasting market trends through 2030. The report analyzes growth drivers including pet ownership patterns, agricultural modernization, and the One Health movement, while examining competitive positioning of major players like IDEXX, Zoetis, Antech, Roche, and Thermo Fisher across various diagnostic assay types, animal categories, and applications.

The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.

The global livestock monitoring market is projected to grow from $6.2 billion in 2025 to $10.3 billion by 2030 at a 10.6% CAGR, driven by AI-enabled precision farming, IoT sensors, and wearable technologies. Europe leads with 33.2% market share, while regulatory compliance and rising protein demand are key growth catalysts.

The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.

IDEXX Laboratories reported strong Q1 2026 results with EPS of $3.47 (beating consensus of $3.41) and sales of $1.14 billion (above consensus of $1.109 billion), driven by higher clinical visits and diagnostic frequency. The company raised its full-year 2026 guidance for both earnings ($14.45-$14.90 vs. previous $14.29-$14.80) and sales ($4.675-$4.76 billion vs. previous $4.63-$4.72 billion). Shares were up 3.35% in premarket trading.

The global veterinary reference laboratory market is projected to grow from USD 6.12 billion in 2025 to USD 13.93 billion by 2035, driven by rising pet ownership, pet humanization trends, and increased demand for advanced diagnostics. However, high infrastructure costs and shortage of skilled specialists pose challenges to market expansion.

IDEXX Laboratories reported better-than-expected Q4 2025 earnings of $3.08 per share (beating $2.94 consensus) with $1.091 billion in sales (beating $1.073 billion consensus) and strong growth across segments. The company issued 2026 guidance of $14.29-$14.80 EPS and $4.632-$4.720 billion in sales. Despite the positive results and strong innovation pipeline, IDEXX shares fell 5.57% to $633.10, likely due to guidance slightly below consensus expectations and ongoing end-market visit weakness concerns.

Idexx Laboratories reported strong Q3 2025 financial results, with revenue growing 13% to $1.11 billion and net income rising 18%. The company beat analyst expectations and raised its full-year guidance, leading to a significant stock price increase.

Wall Street opened mixed on Monday, with AI-driven mega-cap stocks rallying while broader markets remained cautious. Nvidia and Amazon saw significant gains, while cryptocurrencies experienced notable declines.

Five S&P 500 stocks outperformed in August 2025, including Albemarle, UnitedHealth Group, Intel, Humana, and Idexx Laboratories, each with unique factors driving their stock price increases.

The veterinary oncology market is projected to grow from $1.84 billion in 2025 to $3.55 billion by 2030, driven by technological advances, rising pet ownership, and increasing demand for advanced cancer treatments in veterinary medicine.